Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • G. D. Demetri, Harvard University
  • ,
  • C. R. Antonescu, Memorial Sloan-Kettering Cancer Center
  • ,
  • B. Bjerkehagen, University of Oslo
  • ,
  • J. V.M.G. Bovée, Leiden University
  • ,
  • K. Boye, University of Oslo
  • ,
  • M. Chacón, Instituto Alexander Fleming
  • ,
  • A. P. Dei Tos, University of Padova
  • ,
  • J. Desai, University of Melbourne
  • ,
  • J. A. Fletcher, Harvard University
  • ,
  • H. Gelderblom, Leiden University
  • ,
  • S. George, Dana-Farber Cancer Institute
  • ,
  • A. Gronchi, IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • ,
  • R. L. Haas, Netherlands Cancer Institute
  • ,
  • N. Hindi, University of Seville, Hospital Universitario Virgen del Rocio
  • ,
  • P. Hohenberger, Heidelberg University 
  • ,
  • H. Joensuu, University of Helsinki
  • ,
  • R. L. Jones, Royal Marsden NHS Foundation Trust, Institute of Cancer Research
  • ,
  • I. Judson, Institute of Cancer Research
  • ,
  • Y. K. Kang, University of Ulsan
  • ,
  • A. Kawai, National Cancer center
  • ,
  • A. J. Lazar, University of Texas MD Anderson Cancer Center
  • ,
  • A. Le Cesne, Institut Gustave Roussy
  • ,
  • R. Maestro, IRCCS Centro di Riferimento Oncologico - Aviano PN
  • ,
  • R. G. Maki, University of Pennsylvania
  • ,
  • J. Martín, University of Seville, Medical Oncology Department, Hospital Universitario Virgen del Rocio
  • ,
  • S. Patel, University of Texas MD Anderson Cancer Center
  • ,
  • F. Penault-Llorca, Centre Jean Perrin
  • ,
  • C. Premanand Raut, Harvard University
  • ,
  • P. Rutkowski, Maria Sklodowska-Curie Institute of Oncology
  • ,
  • A. Safwat
  • M. Sbaraglia, University of Padova
  • ,
  • I. M. Schaefer, Harvard University
  • ,
  • L. Shen, Chinese Academy of Medical Sciences
  • ,
  • C. Serrano, Autonomous University of Barcelona
  • ,
  • P. Schöffski, KU Leuven
  • ,
  • S. Stacchiotti, IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • ,
  • K. Sundby Hall, University of Oslo
  • ,
  • W. D. Tap, Memorial Sloan-Kettering Cancer Center
  • ,
  • D. M. Thomas, Garvan Institute of Medical Research
  • ,
  • J. Trent, University of Miami
  • ,
  • C. Valverde, Autonomous University of Barcelona
  • ,
  • W. T.A. van der Graaf, Netherlands Cancer Institute, Radboud University Nijmegen
  • ,
  • M. von Mehren, Fox Chase Cancer Center
  • ,
  • A. Wagner, Dana-Farber Cancer Institute
  • ,
  • E. Wardelmann, University of Münster
  • ,
  • Y. Naito, National Cancer Center Hospital East
  • ,
  • J. Zalcberg, Monash University, Department of Medical Oncology, Alfred Health Radiation Oncology
  • ,
  • J. Y. Blay, Universite Claude Bernard Lyon 1

Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.

OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind31
Nummer11
Sider (fra-til)1506-1517
Antal sider12
ISSN0923-7534
DOI
StatusUdgivet - nov. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 200021906